The NHS is set to expand its vaccine programme against respiratory syncytial virus (RSV), aiming to offer protection to a broader group of adults at risk from September. The new phase of the rollout will include adults aged 65 to 74 who have chronic respiratory conditions.

RSV is a common respiratory virus that typically causes cold-like symptoms but can lead to severe illness, especially in older adults and individuals with underlying health issues. The vaccine programme was introduced to reduce hospitalisations and complications linked to RSV infections within vulnerable populations.

Previously, the jab was available primarily to higher-risk groups, but health authorities decided to widen eligibility following evidence on the virus’s impact and vaccine effectiveness. By targeting adults over 65 with chronic respiratory diseases, officials hope to provide better protection for people susceptible to severe RSV-related complications.

The move aligns with ongoing efforts to prevent respiratory illnesses among older adults as seasonal respiratory viruses continue to pose significant health challenges. The expansion comes as part of a broader strategy within the NHS to enhance immunisation coverage against respiratory infections that can severely affect certain patient groups.

Vaccinations will be available through participating healthcare providers, with the NHS advising eligible individuals to seek advice and book appointments ahead of the upcoming RSV season. The programme’s extension highlights the importance placed on protecting vulnerable populations and reducing the healthcare burden associated with respiratory infections.